Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

BACKGROUND: As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with fast...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cost Eff Resour Alloc
Glavni autori: McEwan, Phil, Webster, Samantha, Ward, Thomas, Brenner, Michael, Kalsekar, Anupama, Yuan, Yong
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2017
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5521139/
https://ncbi.nlm.nih.gov/pubmed/28736505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-017-0077-4
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items